Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.70 |
| ▸ | PIM1 | P11309 | 2/20 | 0.67 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 10/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.62 |
| ▸ | MYC | P01106 | 1/20 | 0.61 |
| ▸ | IL1RN | P18510 | 1/20 | 0.61 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212733 | 1.00 | GPR35 (0.70) | GPR35PIM1PIM2HPGDPTGS2 | |
| SCHEMBL212735 | 1.00 | GPR35 (0.70) | GPR35PIM1PIM2HPGDPTGS2 | |
| SCHEMBL212025 | 0.87 | MYC (0.77) | GPR35PIM1PIM2HPGDPTGS2 | |
| SCHEMBL5672232 | 0.87 | MYC (0.77) | GPR35PIM1PIM2HPGDPTGS2 | |
| SCHEMBL212026 | 0.87 | MYC (0.77) | GPR35PIM1PIM2HPGDPTGS2 | |
| SCHEMBL7696597 | 0.87 | CISD1 (0.68) | GPR35PIM1PIM2HPGDPTGS2 | |
| SCHEMBL7696596 | 0.87 | CISD1 (0.68) | GPR35PIM1PIM2HPGDPTGS2 | |
| SCHEMBL9326976 | 0.86 | HPGD (0.80) | GPR35PIM1PIM2HPGDCISD1 | |
| SCHEMBL9326177 | 0.86 | HPGD (0.80) | GPR35PIM1PIM2HPGDCISD1 | |
| SCHEMBL2733862 | 0.86 | PIM1 (0.81) | GPR35PIM1PIM2HPGDCISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | GPR35 4491/4885PIM1 2009/4885PIM2 2680/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | GPR35 4429/4885PIM1 2462/4885PIM2 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.